Pediatric Long-Term Follow-up and Rollover Study
Public ClinicalTrials.gov record NCT03975829. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Open Label, Multi-center Roll-over Study to Assess Long-term Effect in Pediatric Patients Treated With Tafinlar (Dabrafenib) and/or Mekinist (Trametinib)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
A roll-over study to assess long-term effect in pediatric patients treated with dabrafenib and/or trametinib.
Study identification
- NCT ID
- NCT03975829
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 4
- Enrollment
- 163 participants
Conditions and interventions
Conditions
- Diffuse Astrocytoma
- Anaplastic Astrocytoma
- Astrocytoma
- Oligodendroglioma, Childhood
- Anaplastic Oligodendroglioma
- Glioblastoma
- Pilocytic Astrocytoma
- Giant Cell Astrocytoma
- Pleomorphic Xanthoastrocytoma
- Anaplastic Pleomorphic Xanthoastrocytoma
- Angiocentric Glioma
- Chordoid Glioma of Third Ventricle
- Gangliocytoma
- Ganglioglioma
- Anaplastic Ganglioglioma
- Dysplastic Gangliocytoma of Cerebrellum
- Desmoplastic Infantile Astrocytoma and Ganglioglioma
- Papillary Glioneuronal Tumor
- Rosette-forming Glioneuronal Tumor
- Central Neurocytoma
- Extraventricular Neurocytoma
- Cerebellar Liponeurocytoma
- Neurofibromatosis Type 1
Eligibility (public fields only)
- Age range
- 1 Year to 99 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 3, 2019
- Primary completion
- Nov 4, 2026
- Completion
- Nov 4, 2026
- Last update posted
- Aug 26, 2026
2019 – 2026
United States locations
- U.S. sites
- 11
- U.S. states
- 11
- U.S. cities
- 11
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Phoenix Children s Hospital | Phoenix | Arizona | 85016 | — |
| Childrens National Hospital | Washington D.C. | District of Columbia | 20010 | — |
| Nicklaus Childrens Hospital | Miami | Florida | 33155 | — |
| Indiana Uni School of Medicine | Indianapolis | Indiana | 46202-2810 | — |
| Johns Hopkins Hospital | Baltimore | Maryland | 21287 | — |
| Dana Farber Cancer Institute | Boston | Massachusetts | 02215 | — |
| University of Minnesota | Minneapolis | Minnesota | 55455 | — |
| Memorial Sloan Kettering Cancer Ctr | New York | New York | 10065 | — |
| Cinn Children Hosp Medical Center | Cincinnati | Ohio | 45229-3039 | — |
| St Jude Childrens Research Hospital | Memphis | Tennessee | 38105 | — |
| Texas Childrens Hospital | Houston | Texas | 77030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 43 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03975829, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 26, 2026 · Synced Sep 1, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03975829 live on ClinicalTrials.gov.